Skip to main content
. Author manuscript; available in PMC: 2006 Jan 25.
Published in final edited form as: Oncogene. 2005 Jul 21;24(31):4993–4999. doi: 10.1038/sj.onc.1208683

Fig. 1.

Fig. 1

Fig. 1

Fig. 1

Western blot Profiles of Bcl-2 family members after treatment with bortezomib. (A) Human colon carcinoma cell lines (DLD-1, LOVO, SW620 and HCT116), human lung cancer cell H1299 and human ovarian cancer cell SKOV3 were treated with 0.1 to 5- μM bortezomib for 6 hours. (B) DLD1 cells were treated with 1 μM bortezomib for 3–24 hours. (C) Western blot analysis of DLD1 cells treated with MG132 (0.5 to 5 μM) or ALLN (5 to 20 μM) for 24 h. Data represent one of two independent experiments with similar results. (D) Apoptotic cells determined by SubG1 assay in cell samples treated as in (C). The values represent mean + SD of three assays.